Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Interferon-beta Treatment for West Nile Virus
NCT06510426Phase 2Recruiting
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of interferon beta-1a in West Nile virus infection (WNV), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoints: Rates of death or intubation at 4 weeks and Modified Rankin Scale at 6 months. Started Jul 2024; status: recruiting.
02
Drugs
interferon beta-1a
03
Conditions
West Nile virus infection (WNV)
Beyond the preview
Go deeper on NCT06510426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510426.